HUMAHealthcare · BiotechnologyThe 5 Wall Street analysts covering Humacyte, Inc. hold a median 12-month price target of $1.25 — +120.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Humacyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (71): Smaller than most of the companies we track.
Momentum (5): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HUMA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +120.2% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Benchmark | Maintains | Speculative Buy | $2.00 → $1.00 |
| 28 July 2026 | BTIG | Reiterates | Buy | $2.00 |
| 28 July 2026 | BTIG | Reiterates | Buy | — |
| 17 June 2026 | TD Cowen | Maintains | Buy | — |
| 17 June 2026 | TD Cowen | Maintains | Buy | $1.50 → $1.25 |
| 16 June 2026 | BTIG | Reiterates | Buy | — |
| 16 June 2026 | BTIG | Reiterates | Buy | $2.00 |
| 11 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 June 2026 | HC Wainwright & Co. | Maintains | Buy | $3.00 → $4.00 |
| 8 June 2026 | BTIG | Reiterates | Buy | — |
| 1 June 2026 | Benchmark | Maintains | Speculative Buy | — |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | TD Cowen | Maintains | Buy | — |
| 13 May 2026 | BTIG | Maintains | Buy | — |
| 28 Apr 2026 | BTIG | Reiterates | Buy | — |
| 28 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 24 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 21 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | Barclays | Maintains | Overweight | — |
| 31 Mar 2026 | Benchmark | Downgrade | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HUMA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Humacyte, Inc. returned −62.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 5% of US stocks
Cheaper than 20% of US stocks
Cheaper than 69% of US stocks
Higher than 80% of US stocks
Higher than 68% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Humacyte, Inc. has a market value of $157.7M and an enterprise value of $144.7M.
Revenue in the twelve months to 30 June 2026: $2.1M. The latest quarter grew 34.9% year on year.
Net income over the same four quarters: −$96.7M, a −4560.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$97.6M.
Trailing P/E: −2.2×; forward P/E: −2.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Humacyte, Inc. employs 184 people — $12K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Humacyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Humacyte, Inc. announced that Laura Niklason, M.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made via press release on September 10, 2026.
Why it matters — HUMA watchers would care because the company's participation in a major investment conference provides an opportunity for exposure to the investment community.
Humacyte announced that the FDA has authorized an extension of the expiration dating period for its Symvess product from 18 months to 36 months when stored refrigerated at 2°C to 8°C. The extended shelf life is supported by stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month period.
Why it matters — A longer authorized shelf life for Symvess could reduce product waste and improve supply-chain logistics for Humacyte, a commercially relevant development for the company's flagship offering.
Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti Jr., announced it is continuing its investigation into the officers and directors of Humacyte, Inc. The investigation follows the company's August 9, 2024 announcement that the FDA will require additional time to complete its review of its Biologic License Application for its acellular tissue engineering product.
Why it matters — A continuing law-firm investigation into Humacyte's leadership, tied to the FDA's extended review of its BLA, is significant for shareholders monitoring potential legal and regulatory developments affecting the company.
Humacyte confirmed it plans to file a supplemental Biologics License Application (BLA) with the FDA for its ATEV product in the dialysis access indication, following discussions with the FDA. The filing is expected in November 2026.
Why it matters — A confirmed regulatory timeline for the ATEV dialysis access indication gives Humacyte watchers visibility into a potential expansion of the company's product pipeline.
Kahn Swick & Foti, LLC announced it is continuing its investigation into the officers and directors of Humacyte, Inc. The announcement was made by former Attorney General of Louisiana, Charles C. Foti Jr., Esq.
Why it matters — HUMA watchers would care because an ongoing legal investigation into the company's officers and directors could be significant news regarding corporate oversight.
The 5 Wall Street analysts covering Humacyte, Inc. have a median 12-month price target of $1.25, with estimates ranging from $1 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Humacyte, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Humacyte, Inc. 17 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Humacyte, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (71 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +120.2% from the last close, and Ticker Nerd's factor model ranks Humacyte, Inc. 17 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Humacyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HUMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $4 over the next 12 months.
Humacyte, Inc. returned -62.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Humacyte Inc. is a biotechnology company focused on developing and manufacturing off-the-shelf, bioengineered human tissues designed to be universally implantable.
The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference". Humacyte, Inc. announced that Laura Niklason, M.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made via press release on September 10, 2026.
Humacyte Inc. is a biotechnology company focused on developing and manufacturing off-the-shelf, bioengineered human tissues designed to be universally implantable. Its core platform centers on acellular tissue technologies, including human acellular vessels, that are intended to support vascular repair and reconstruction across multiple medical settings. The company’s products and programs address critical needs in areas such as vascular trauma, hemodialysis access, peripheral arterial disease, and other regenerative medicine applications. Humacyte also works on advanced tissue constructs and organ systems, positioning its technology at the intersection of regenerative medicine, bioengineering, and surgical care. Headquartered in Durham, North Carolina, Humacyte serves the healthcare market through its commercial-stage development and manufacturing capabilities.
CEO Dr. Laura E. Niklason M.D., Ph.D. · 184 employees · United States · https://www.humacyte.com
